The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J02 | Antimycotics for systemic use | |
| 3 | J02A | Antimycotics for systemic use | |
| 4 | J02AX | Other antimycotics for systemic use | |
| 5 | J02AX06 | Anidulafungin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 0.1 g |
| Active Ingredient | Description | |
|---|---|---|
| Anidulafungin |
Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of Aspergillus nidulans. Anidulafungin selectively inhibits 1,3-β-D glucan synthase, an enzyme present in fungal, but not mammalian cells. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ECALTA Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ERAXIS Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
